In an effort to characterize active principles for diabetic complication from medicinal mushroom, aldose reductase inhibitors were isolated from the fruiting body of Phellinus linteus and identified as hispidin (5), phelligridimer A (6), davallialactone (7), methyldavallialactone (8), hypholomine B (9), interfungins A (10), and inoscavin A (11), together with protocatechuic acid (1), protocatechualdehyde (2), caffeic acid (3), and ellagic acid (4). Their structures were elucidated by spectroscopic analyses. Among them, davallialactone (7), hypholomine B (9), and ellagic acid (4) exhibited potent rat lens aldose reductase and human recombinant aldose reductase inhibitory activity with IC 50 values of 0.33, 0.82, 0.63 m mM and 0.56, 1.28, 1.37 m mM, respectively.
Diabetes mellitus is a leading cause of many complications such as atherosclerosis, cardiac dysfunction, retinopathy, neuropathy, and nephropathy. 1) Aldose reductase (alditol/ NADP ϩ oxidoreductase, E.C.1.1.1.21, ALR2), the first enzyme in the polyol pathway, catalyzes the reduction of the aldehyde form of D-glucose to D-sorbitol with concomitant conversion of NADPH to NADP ϩ ( Fig. 1) .
2) It is generally accepted that this polyol pathway plays an important role in the development of some degenerative complications of diabetes. The elevated blood glucose levels that are characteristic of diabetes mellitus cause a significant flux of glucose through the polyol pathway in tissues such as nerves, retina, lens, and kidney, where glucose uptake is independent of insulin. 3, 4) Further, superfluous consumption of NADPH through the polyol pathway could induce or exacerbate intracellular oxidative stress. [3] [4] [5] Thus, aldose reductase inhibitors (ARIs) are an attractive pharmacological target for the treatment of diabetic complications.
Mushrooms are nutritionally functional foods and important sources of physiologically beneficial medicines. They produce various classes of secondary metabolites with interesting biological activities and thus have the potential to be used as valuable chemical resources for drug discovery. 6, 7) Several mushrooms belonging to the genera Inonotus and Phellinus have been used as traditional medicines for the treatment of gastrointestinal cancer, cardiovascular disease, heart diseases, stomach ailments, and diabetes. [8] [9] [10] Interestingly, these mushrooms commonly produce a number of yellow antioxidant pigments that comprise hispidin derivatives and polyphenols. Phellinus linteus, which is commonly referred to as Sangwhang in Korea, has been reported to have strong antioxidant and b-secretase inhibitory activity [11] [12] [13] as well as apoptotic and anti-complement activity. 14, 15) Its known active principals are hispidin, hispolon, and phellinusfurans A and B.
11-15) Davallialactone, methyldavallialactone, inoscavin A, and interfungins A-C from the fungus Inonotus xeranticus [16] [17] [18] and hypholomine B from Hypholoma fasciculare, 19) phelligridimer A and phelligridin C-J from Phellinus igniarius 20) have also been reported. However, it was the first time that hispidin derivatives including compounds 6-11 were isolated from the fruiting body of P. linteus. Moreover, till date, there have been no studies of the effect of mushroom's constituents on aldose reductase inhibitory activity. Therefore, we investigated the inhibitory effect of the fruiting body of P. linteus on ALR2 in order to evaluate its potential in treating diabetic complications. This paper reports the isolation and structural elucidation of the compounds with inhibitory activity against rat lens aldose reductase (RLAR) and human recombinant aldose reductase (HRAR).
MATERIALS AND METHODS

Chemicals
The 1 H-and 13 C-NMR spectra were recorded on a Bruker DPX 400 spectrometer (Karlsrube, Germany) at 400 and 100 MHz, respectively. Chemical shifts are given in ppm (d) using tetramethylsilane as an internal standard. DLglyceraldehyde, the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH), and quercetin were purchased from Sigma (St. Louis, MO, U.S.A.). Sephadex LH 20 (GE Healthcare Bio-Science AB, Sweden) and cosmosil 75C18-OPN (Nacalai Tesque, Kyoto, Japan) were used as the column packing material. HRAR was purchased from Wako Pure Chemical Industries (Osaka, Japan).
Plant Materials The fresh mushroom P. linteus was presented by the Samsung Hurb Medicine Co., Ltd., Chuncheon, Korea and the voucher specimen (No. RIC-021) was deposited and maintained at the Herbarium of Regional Innovation Center, Chuncheon, Korea.
Isolation and Identification The lyophilized fruiting body of P. linteus (1 kg) was extracted 3 times with methanol (MeOH) for 5 h. After removal of MeOH under reduced pressure, a dark brown residue (50 g, 5%) was obtained. The residue was suspended in water and then partitioned sequentially with n-hexane (7 g, 0.7%), methylene chloride (5.9 g, 0.59%), ethylacetate (EtOAc, 24 g, 2.4%), n-butanol (12.5g, 1.3%), and water (1 g, 0.1%). The active compounds were purified from the EtOAc-soluble portion by a bioassayguided separation. The EtOAc fraction was subjected to a Sephadex LH 20 column chromatography eluted with MeOH to obtain 12 fractions. From fractions 1-3, compound 1 (10 mg), compound 2 (9 mg), and compound 3 (11 mg) were isolated using a preparative HPLC with 15% acetonitrile (MeCN). Fraction 4 was recrystallized to obtain compound 4 (15 mg). Compound 5 (12 mg) from fraction 5 and compound 6 (10 mg) from fraction 7 were purified by using a middle-pressure liquid chromatography over a reversedphase Si gel (C-18) eluting with a gradient of increasing MeCN (20 to 45%) in water and subsequent preparative HPLC with 25 or 30% MeCN. Compound 7 (11 mg) and compound 8 (11 mg) from fraction 8 and compound 9 (13 mg), compound 10 (10 mg), and compound 11 (10 mg) from fraction 11 were isolated using the above-mentioned method.
Assay for Rat Lens Aldose Reductase Inhibitory Activity Crude aldose reductase was prepared as follows: Rat lenses were removed from Sprague-Dawley rats weighing 250-280 g and frozen until required. The rat lens homogenate was prepared according to the method of Hayman and Kinoshita with some modifications. 21) A partially purified enzyme with a specific activity of 6.5 U/mg was routinely used to test the enzyme inhibition. The partially purified material was separated into 1.0 ml aliquots and stored at Ϫ40°C. RLAR activity was assayed spectrophotometrically by measuring the decrease in the absorption of NADPH at 340 nm over a 4-min period with DL-glyceraldehyde as the substrate. The plant extract or pure compound was dissolved in dimethyl sulfoxide (DMSO). Each 1.0 ml cuvette contained equal units of the enzyme, 0.10 M sodium phosphate buffer (pH 6.2), 0.3 mM NADPH, with or without 10 mM of the substrate and an inhibitor. 22, 23) The concentration of inhibitors giving 50% inhibition of enzyme activity (IC 50 ) was calculated from the least-squares regression line of the logarithmic concentrations plotted against the residual activity.
Assay for Human Recombinant Aldose Reductase Inhibitory Activity HRAR activity was carried out at 37°C in a 100 mM potassium phosphate buffer (pH 6.2) containing 10 mM DL-glyceraldehyde, 150 mM NADPH, and HRAR in a total volume of 1.0 ml. 24) The reaction was initiated by adding the substrate and the rate of NADPH oxidation was monitored by recording the decrease in absorbance at 340 nm. The concentration of inhibitors giving IC 50 was calculated from the least-squares regression line of the logarithmic concentrations plotted against the residual activity.
RESULTS AND DISCUSSION
Even though numerous trials for the treatment of diabetic complications have been conducted over the last 20 years with synthetic compounds, pharmacokinetic problems connected to these ARIs, together with the length of trials, have resulted in the lack of observed efficacy. Synthetic ARIs are currently available and many have been tested for their clinical use, albeit with limited success. Thus, there is still an urgent need for new ARIs. 1, 2) In order to identify the active compounds from P. linteus, its extract was systematically divided into 5 fractions, which were then tested for RLAR inhibitory activity. Among them, the EtOAc fraction was found to exhibit the strongest RLAR inhibitory activity, its IC 50 being 4.09 mg/ml (Table 1) . Since this result suggests the likelihood of many ARIs in the EtOAc soluble fraction, attention should be focused on isolating the ARI from this fraction. The active EtOAc fraction was subjected to repeated chromatography on a Sephadex LH 20 and a reversed-phase Si gel to yield compounds 1-11. The structures of these compounds were elucidated based on 1-dimensional ( 1 H-and 13 C-NMR) and 2-dimensional NMR (HMQC and HMBC) spectral data and by comparison with published spectral data. [16] [17] [18] [19] [25] [26] [27] [28] [29] [30] [31] [32] They were identified as protocatechuic acid (1), protocatechualdehyde (2), caffeic acid (3), ellagic acid (4), hispidin (5), phelligridimer A (6), davallialactone (7), methyldavallialactone (8) , hypholomine B (9), interfungins A (10), and inoscavin A (11). The chemical structures of compounds 1-11 isolated from the fruiting body of P. linteus are shown in Fig. 2 .
Compounds 6-11 are highly oxygenated and functionalized aromatic compounds that possess the unique basic structural unit, namely, 6-[2-(3,4-dihydroxyphenyl)ethenyl]-4-hydroxy-2H-pyran-2-one (hispidin, 5) moiety. In terms of biogenesis, it was reported that compound 9, which has an unusual structure with 2,3-dihydro-4-H-furo[3,2-c]pyran-4-one, may be biosynthesized by the oxidation coupling of two hispidin mediates, while compound 6 may be sequentially or simultaneously formed by the oxidation coupling of four hispidin mediates and/or by oxidation coupling of 2 mol of hypholomine B (9). 29) Compounds 7, 8, and 11 are known to be biosynthesized by rearrangement of compound 10, which is biosynthesized by the condensation of hispidin and 6-(3,4-dihoxryophenyl)-4-hydroxy-3,5-hexadiene-2-one (hispolon). 18) Inhibitory activities against RLAR and HRAR of compounds 1-11 were evaluated. For RLAR and HRAR, DLglyceraldehyde and NADPH were used as substrate and cofactor, respectively. As shown in Table 2 , compound 4 showed strong inhibition against RLAR (IC 50 0.63 mM) and HRAR (IC 50 1.37 mM) activity, while compound 1 and com- There was no particular relationship between structure and inhibitory activity within hispidin dimers (7) (8) (9) (10) (11) . However, hispidin dimers exhibited stronger inhibition than hispidin itself (5) or hispidin tetramer (6). Lee et al. have shown that the structure requirements for AR inhibitory activity are a generally planar structure with two aromatic hydrophobic regions and a common region susceptible to charge-transfer interactions. By combining the spatial position of ARIs with binding modes and inhibitory activities, the pharmacophore requirements of the ARIs were reported as follows (Fig. 3) . 34) An ionized portion [R1ϭcatechol moiety (7-9, 11) or a,bunsaturated carbonyl group (10)] of ARI forms hydrogen bonding interactions with the side-chains of Tyr48, His110, and Trp111, while an aromatic portion (R2ϭsix-membered lactone ring) forms aromatic interactions with the side-chains of Trp20, Trp111, and Phe122. The aromatic portion also forms hydrogen-boding interactions with Cys298 and main chain of the N-H of Leu300. A side-chain (R3ϭcatechol moiety) intercalates between Trp111 and Leu300 to improve the aromatic-aromatic interactions further.
It has been acknowledged that plant-derived extracts and phytochemicals are potential alternatives to synthetic inhibitors against AR. Currently, the compounds isolated from plants as ARIs are classified as flavonoids, stilbenes, ellagic acid and its derivatives, and alkaloids. 35) In the present study, hispidin derivatives from P. linteus possess strong ALR2 inhibitory effects and could be potential lead compounds for further development as natural drugs for diabetic complications.
